Meeting
2021 ASCO Annual Meeting
Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) (CaNI) for advanced renal cell carcinoma with variant histology (aRCCVH).
Authors
Bradley Alexander McGregor
Dana-Farber Cancer Institute, Boston, MA
Bradley Alexander McGregor , Wanling Xie , Mehmet Asim Bilen , David A. Braun , Wenxin Xu , Praful Ravi , Elisabeth I. Heath , David F. McDermott , Rana R. McKay , Hans J. Hammers , Toni K. Choueiri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT04413123
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS4592)
DOI
10.1200/JCO.2021.39.15_suppl.TPS4592
Abstract #
TPS4592
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Efficacy, safety, and tolerability of tivozanib (TIVO) in heavily pretreated patients (pts) with advanced clear-cell renal cell carcinoma (ccRCC).
First Author: Andrew Johns
Poster
2023 ASCO Annual Meeting
Nivolumab and ipilimumab in advanced non small cell lung cancer previously treated with PD1 axis inhibition.
First Author: Scott N. Gettinger
Poster
2023 ASCO Genitourinary Cancers Symposium
A pilot trial evaluating the rapid sequencing of approved therapies in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC).
First Author: Qian Qin
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases.
First Author: Jianbo Wang